濮阳东方男科医院割包皮好不好濮阳东方医院看阳痿评价很不错,濮阳东方医院坐公交路线,濮阳东方医院妇科做人流非常好,濮阳东方医院看妇科技术很专业,濮阳东方医院男科收费查询,濮阳东方医院男科治早泄口碑好收费低,濮阳东方医院男科治疗阳痿口碑好收费低

SINGAPORE, Sept. 7 (Xinhua) -- Singapore scientists have found possible new ways to treat a type of aggressive breast cancer that is unresponsive to current forms of treatment, local broadcaster Channel NewsAsia reported on Wednesday.The team of scientists at the Genome Institute of Singapore ( GIS) and National University of Singapore (NUS), led by GIS senior group leader Qiang Yu, found that the enzyme EZH2 acts by inhibiting genes that stop the growth of tumors in the body.The insights could open the door to developing more effective treatment for fast spreading breast cancers, especially the estrogen receptor-negative breast cancer that is common all over the world.It was also found that through EZH2, cancer is promoted in the body by activating specific genes that impact breast cancer progression and cancer stem cell self-renewal.Yu said the new understanding on how EZH2 works as a cancer- causing gene in breast cancer has important therapeutic implication."The results suggest that small molecule drugs that block enzyme activity of EZH2 may not work for cancers caused by EZH2's activation genes," Yu said.Currently pharmaceutical companies have been developing drugs only to the block EZH2 enzyme activity so that tumor suppressers can perform their protective role in blocking cancer growth.Researchers said the next step would be to develop biomarkers to identify tumors with EZH2.This step would enable better treatment methods, with one of options being the development of therapies that shut down EZH2 completely and not just inhibit its enzymatic function.The findings have been published on the journal Molecular Cell.

BEIJING, July 11 (Xinhuanet) -- U.S. federal government officially announced that it denied the medical use of marijuana."Department of Health and Human Services concluded that marijuana has a high potential for abuse, has no accepted medical use in the United States, and lacks an acceptable level of safety for use even under medical supervision," U.S. Department of Justice declared Friday.The announcement will keep marijuana in the classification of dangerous, addictive drug as heroin.The decision comes almost nine years after medical marijuana advocates asked the government to reclassify marijuana, as its therapeutic effectiveness in treating some diseases and relieving pain of patients.Joe Elford, the chief counsel for Americans for Safe Access (ASA), said he was not surprised by the government's disapproval."It is clearly motivated by a political decision that is anti-marijuana," He noted.This is the third petition to reclassify marijuana has failed to be approved. The former two were filed in 1972 and in 1995, respectively.

SYDNEY, Aug. 2 (Xinhua) -- Australia's general practitioners ( GPs) will not back the idea of routine prostate cancer tests for men as young as 40 despite growing calls for regular screening, the nation's largest professional general practice organization said on Tuesday.Spokesman for the Royal Australian College of General Practitioners (RACGP), Professor Chris Del Mar said there was not enough solid evidence to suggest major benefits from routine screening and that current tests were unable to detect "nasty" and potentially deadly forms of prostate cancer from ones that will not cause any harm."The problem is you end up treating lots of people who don't need to be treated," Del Mar said, adding that treatment could leave men impotent and with incontinence problems."You will treat 20 times as many people than would have ever been bothered by it. We don't yet know that treating prostate cancer is better than not treating it. We are not sure it does any good and could be doing more harm," he said.On the other hand, Australia's urologists and pathologists both want men aged 40 and over who are worried about developing the disease to be offered tests.The Royal College of Pathologists (RCPA) on Tuesday released an official recommendation on routine screening for men aged 40 and over if they were concerned about prostate cancer.The pathologists argue that blood tests for prostate cancer in men under 50 can predict their future risk of developing the disease by measuring their prostate specific antigen levels (PSA).They say that men with high PSA levels for their age should be tested annually, while those PSA levels are below the average could be tested less frequently.Their call for more routine testing contrasts with recommendations for GPs, whose `Red Book' medical guide does not support regular screening.Instead, it suggests GPs should inform men aged 50-70 of the risks and benefits of screening and only test if the patient requests one.RACGP spokesman Del Mar, who co-wrote the RACGP's recommendations, said while the Red Book was being revised "we are not going to liberalize it".Prostate cancer is one of the most common forms of cancer in Australia.About 20,000 cases of prostate cancer are diagnosed each year, with 3,300 men dying.Given the debate around prostate cancer tests, the Royal College of Pathologists wants to work with GPs, urologists and other medical organizations to develop a consensus on how and when to test for the disease, in a similar way to how experts approach breast cancer."It would be a good outcome for prostate cancer if we worked towards developing more of an umbrella document which reflected consensus among different stakeholder organizations. ," RCPA President Paul McKenzie said.

BEIJING, Aug. 24 (Xinhuanet)-- A new study shows that a diet rich in cholesterol-friendly foods, such as soy products and tree nuts, can decrease LDL (bad) cholesterol significantly, according to media reports on Tuesday.The study, published in the Journal of the American Medical Association, found that people who ate a healthy diet filled with cholesterol-lowering foods experienced a 13 percent decrease in their LDL cholesterol levels.For patients with high levels of so-called bad cholesterol, doctors usually have two prescriptions: cholesterol-lowering statin drugs and a diet that cuts out foods high in saturated fat, such as ice cream, red meat and butter.But the new study found that when it comes to lowering artery-clogging cholesterol, what you eat may be more important than what you don't eat.David Jenkins of St. Michael's Hospital and the University created the "portfolio diet," which includes regular consumption of tree nuts and high amounts of fiber from oats, barley and vegetables. The diet, which replaces butter with plant sterol-enriched margarine and substitute soy-based products for meat, allows maximum benefit in lowering cholesterol and preventing heart disease. "The study highlighted the power of food to lower risk for cardiovascular disease: What you do eat and what you don't eat are both important," said Dr. Jane Klauer, a New York internist specializing in metabolism and nutrition.A high overall cholesterol level makes a person nearly twice as likely to suffer a heart attack or stroke as someone whose total cholesterol falls into a healthy range.

WASHINGTON, July 5 (Xinhua) -- Intake of high levels of folate, a water-soluble B vitamin that occurs naturally in food, may reduce colorectal cancer risk, according to a new study published Tuesday in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute. "We found that all forms and sources of folate were associated with lower risk of colorectal cancer," said lead author Victoria Stevens, of the American Cancer Society. "The strongest association was with total folate, which suggests that total folate intake is the best measure to define exposure to this nutrient because it encompasses all forms and sources."Total folate includes naturally occurring food folate and folic acid from fortified foods and dietary supplements.The research team investigated the association between folate intake and colorectal cancer among 99,523 participants in the Cancer Prevention Study II Nutrition Cohort; a total of 1,023 participants were diagnosed with colorectal cancer between 1999 and 2007, a period entirely after folate fortification began. Neither higher nor lower risk was observed during the first two years of follow-up (1999 to 2001), while associations were statistically significantly inverse for the subsequent years (2002 to 2007). The findings of this study add to the epidemiologic evidence that high folate intake reduces colorectal cancer incidence.Folates are essential nutrients needed to make components used for functions required for normal cell growth, including DNA synthesis and repair. Because these processes are critical for cell growth and differentiation, the relationship between folate intake and cancer development has been investigated in several cancers, and most extensively in colorectal cancer.